Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on LATAM Technology Reporter.
Press releases published on August 11, 2025
Mevolaxy Announces Record Payouts in June
GlobeNewswire
·
August 11, 2025
Los Angeles, CA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- June 2025 was the most profitable month in Mevolaxy's history - distributing over $3 million to users through mevstake. This success resulted from a well-thought-out profit distribution model and the …
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
GlobeNewswire
·
August 11, 2025
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, …
MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will …
Rail Vision Receives European Patent for Innovative Locomotive Imaging Technology
GlobeNewswire
·
August 11, 2025
Ra’anana, Israel, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related market, today announced …
Altimmune Board of Directors Appoints Jerry Durso as Chairman
GlobeNewswire
·
August 11, 2025
Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) …
Avicanna Announces US Patent and Trademark Office Issuance of New Patent
GlobeNewswire
·
August 11, 2025
USPTO Issues Patent No. US 12,343,315 B2 covering topical cannabinoid compositions for clear skin TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on …
MAX Power Partners with Caram Media and TMI Digital to Drive Strategic Marketing and Spotlight Natural Hydrogen Story
GlobeNewswire
·
August 11, 2025
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) (“MAX Power” or the “Company”) is pleased to announce strategic partnerships with Caram Media Inc. (“Caram”) and TMI Digital (“TMI …
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
GlobeNewswire
·
August 11, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial …
SixSense Raises $8.5M Funding to Power AI-Driven Semiconductor Manufacturing
GlobeNewswire
·
August 11, 2025
SINGAPORE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- SixSense, a pioneer in AI for semiconductor manufacturing, announced a new round of funding led by Peak XV’s Surge (formerly Sequoia India …
SixSense 獲得 850 萬美元資金以推動 AI 驅動的半導體製造
GlobeNewswire
·
August 11, 2025
新加坡, Aug. 11, 2025 (GLOBE NEWSWIRE) -- SixSense，一家半導體製造領域的 AI 先驅，宣佈了新的資金將由 Peak XV 的 Surge（前身為 Sequoia India …
Lithium Argentina Reports Second Quarter 2025 Results
GlobeNewswire
·
August 11, 2025
ZUG, Switzerland, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Lithium Argentina AG (“Lithium Argentina” or the “Company”) (TSX: LAR) (NYSE: LAR) today announced its second quarter 2025 results. Unless otherwise stated, results are presented in United States dollar. …
Bitget Lists Xeleb Protocol (XCX) for Spot Trading
Chainwire
·
August 11, 2025
Victoria, Seychelles, August 11th, 2025, Chainwire Bitget, the leading cryptocurrency exchange and Web3 company, has announced the listing of Xeleb Protocol (XCX) in the Innovation and AI Zone, adding it for spot trading. Trading for the XCX/USDT pair will …
Plum Role Model™ Named a 2025 Top HR Product of the Year by HR Executive
GlobeNewswire
·
August 11, 2025
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revolutionary pre-hire assessment provider Plum today announced that its newest innovation, Plum Role Model™, has been recognized as a Top HR Product of 2025 by HR Executive. The company will be honored on Monday …
Kraig Biocraft Laboratories to Launch Operations at New Southeast Asia Production Facility This Week
GlobeNewswire
·
August 11, 2025
ANN ARBOR, Mich., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it will begin operations this week at its newest production facility. …
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
GlobeNewswire
·
August 11, 2025
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private …
BioCryst Announces Departure of Dr. Helen Thackray
GlobeNewswire
·
August 11, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an …
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
GlobeNewswire
·
August 11, 2025
Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studies Trial initially taking place in the U.S., following IND clearance Initial data expected in mid-2026 from open-label Phase 1 study in advanced solid tumors …
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
GlobeNewswire
·
August 11, 2025
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track …
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3- or 6-month maintenance dosing, a …
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
GlobeNewswire
·
August 11, 2025
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with …